Add BrightSurf on Google Email

Recreating a hallmark of Parkinson's disease in human neurons

Researchers create Lewy bodies in living dopaminergic neurons using human stem cells and find that immune challenge is crucial for their formation. The study identifies a previously unknown link between the immune system and neurological disease, suggesting that genetic predisposition may not be necessary for Parkinson's development.

SourceMcGill University·JournalNature Neuroscience·TypeExperimental study·DateOct 8, 2024

Promising ‘first’ in Alzheimer’s drug development

Researchers have developed a peptide inhibitor called RI-AG03 that effectively prevents Tau protein aggregation in lab and fruit fly studies. The breakthrough targets both major aggregation-promoting 'hotspots' of the Tau protein, potentially paving the way for more effective treatments for neurodegenerative diseases.

SourceLancaster University·JournalAlzheimer s & Dementia·TypeExperimental study·DateOct 3, 2024

New molecules from IOCB Prague decrease appetite and protect the brain against Alzheimer’s-type diseases

Scientists at IOCB Prague have developed a new compound that suppresses appetite and protects the brain against Alzheimer's disease. The modified molecule, derived from the neuropeptide CART, is effective in reducing pathology associated with Alzheimer's.

SourceInstitute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB Prague)·JournalEuropean Journal of Pharmacology·TypeExperimental study·DateAug 21, 2024

Science in Space to Cure Disease on Earth—the International Space Station National Lab and NASA announce new funding opportunity

The International Space Station National Laboratory is collaborating with NASA to fund up to $4 million in research addressing significant diseases like cancer, cardiovascular disease, and neurodegenerative disease. The joint solicitation aims to leverage microgravity to improve existing or develop new technologies for health problems ...

ALS diagnosis and survival linked to metals in blood, urine

A University of Michigan-led study found that higher levels of metals in blood and urine are associated with a greater risk for ALS and shorter survival. Occupational exposure to metals was also linked to increased metal levels, emphasizing the need for accounting for environmental factors when evaluating overall exposure risk.

SourceMichigan Medicine - University of Michigan·JournalJournal of Neurology Neurosurgery & Psychiatry·TypeData/statistical analysis·DateAug 6, 2024

Aging-related genomic culprit found in Alzheimer’s disease

Researchers developed a method to study aged neurons in the lab without a brain biopsy, revealing aspects of cells' genomes linked to late-onset Alzheimer's development. The technique suggests new treatment strategies targeting retrotransposable elements and early intervention to slow disease progression.

SourceWashU Medicine·JournalScience·TypeExperimental study·DateAug 1, 2024

Can targeted therapies be applied to patients with Alzheimer's?

University of Utah researchers have developed a targeted therapy approach using alpha particles to break down harmful amyloid beta plaques, potentially slowing the devastating neurodegenerative disease. The treatment, called Targeted Alpha Therapy, delivers particles directly to the plaques while minimizing damage to healthy tissues.

SourceUniversity of Utah·JournalJournal of Nuclear Medicine·TypeObservational study·DateAug 1, 2024

Public health measures that reduce dementia risk could save up to £4bn

A new study suggests that public health interventions, such as reformulating food products and introducing low emission zones, could yield significant cost savings and QALY gains in England. The interventions studied could save up to £4bn by reducing dementia rates and helping people live longer and healthier.

SourceUniversity College London·JournalThe Lancet Healthy Longevity·TypeComputational simulation/modeling·DateJul 31, 2024

Published research from the Parkinson’s Foundation shows genetic variants are more common in people with Parkinson’s disease than originally thought

The PD GENEration study has found that 13% of participants have a genetic form of Parkinson's disease, significantly higher than previous estimates. The study, which reached its goal of 15,000 participants ahead of schedule, provides insights into the genetics of the disease and its potential for precision medicine.

SourceParkinson's Foundation·JournalBrain·TypeObservational study·DateJul 29, 2024

“Prelude” to neuromuscular disease SMA may offer chances for better treatment

Researchers found anomalies in embryonic development of individuals with spinal muscular atrophy (SMA), which could lead to new treatment options. These abnormalities were recreated in laboratory-grown tissue cultures called organoids, revealing key insights into the disease's progression.

SourceDZNE - German Center for Neurodegenerative Diseases·JournalCell Reports Medicine·TypeExperimental study·DateJul 26, 2024

Antisense oligonucleotide treatment shows promise in treating Parkinson's disease progression

Researchers from Tokyo Medical and Dental University demonstrate a proof of concept for antisense nucleic acid therapy to prevent the spread of α-synuclein pathologies in synucleinopathies. The treatment, involving antisense oligonucleotides, effectively reduces Lewy pathology-like neuronal inclusion by over 90%.

SourceTokyo Medical and Dental University·JournalActa Neuropathologica Communications·DateJul 25, 2024

Multiple concussions in rugby players change proteins linked to neurodegenerative diseases

A study by Durham University found that retired rugby players with multiple concussions have higher levels of proteins linked to neurodegenerative diseases, such as Alzheimer's and motor neurone disease. The research suggests monitoring athletes' blood for these biomarkers may help diagnose early disease and prevent future development.

SourceDurham University·JournalInternational Journal of Molecular Sciences·TypeObservational study·DateJul 16, 2024

Protein droplets likely don’t cause Parkinson’s

Researchers investigated the relationship between protein aggregation and liquid-liquid phase separation, finding that droplet formation may actually protect against aggregation. The study, led by Paul Scherrer Institute, used over 500 conditions to test the behavior of alpha-synuclein proteins.

SourcePaul Scherrer Institute·JournalAdvanced Science·TypeExperimental study·DateJul 15, 2024

Sant Pau researchers discover a new gene that causes ALS

A study by Sant Pau Research Institute identified a new mutation in the ARPP21 gene linked to amyotrophic lateral sclerosis (ALS) in 10 patients from 7 unrelated families. The finding suggests that ARPP21 is a novel ALS-causing gene with potential for personalized therapies and diagnosis.

SourceInstitut de Recerca Sant Pau (Sant Pau Research Institute)·JournalJournal of Neurology Neurosurgery & Psychiatry·TypeExperimental study·DateJul 12, 2024

Potential new target for early treatment of Alzheimer's disease

A study found that targeting heparan sulfate-modified proteins improves cell repair, rescues neuron loss and reverses cellular changes associated with neurodegenerative diseases. Disrupting these proteins promotes autophagy-dependent cell repair and reverses early cellular problems in models of Alzheimer's.

SourcePenn State·JournaliScience·TypeExperimental study·DateJul 2, 2024

Neuroscience research leverages stem cells to understand how neurons connect and communicate in the brain

Researchers at Colorado State University used human stem cells to study synaptic connections in the brain, focusing on GABAergic synapses. They found that Gephyrin promotes autonomous assembly of these synapses, which can develop independently of neuronal communication. This understanding could lead to new treatments for neurological d...

SourceColorado State University·JournalProceedings of the National Academy of Sciences·DateJun 26, 2024

Slipping a note to a neighbor: The cellular way

Researchers from PSI and ETH Zurich studied connexin-36 gap junction channels and found that antimalarial drug mefloquine binds to the channels, potentially explaining its severe side effects. The study provides new insights into how drugs interact with connexins and may lead to the development of therapies for neurological diseases.

SourcePaul Scherrer Institute·JournalCell Discovery·TypeExperimental study·DateJun 26, 2024

Landmark Nature Medicine study reports promising new treatment reduces suffering in Sanfilippo syndrome

A landmark clinical trial collaboration has reported significant improvements in neurobehavioral and functional outcomes for children with moderate to advanced stages of Sanfilippo syndrome. The study found anakinra, a recombinant interleukin-1 receptor antagonist, to be safe and effective in reducing disease symptoms.

SourceThe Lundquist Institute·JournalNature Medicine·TypeRandomized controlled/clinical trial·DateJun 21, 2024

AI-driven tool for distinguishing Lewy body dementia via changes in vocal emotional expression

A new AI-driven tool can accurately diagnose Lewy body dementia by analyzing changes in vocal emotional expressions. The study found that individuals with Lewy body dementia exhibited more negative and calmer emotional expressions compared to those with Alzheimer's disease and healthy controls.

SourceUniversity of Tsukuba·JournalAlzheimer s & Dementia Diagnosis Assessment & Disease Monitoring·DateJun 4, 2024

Magnetic microcoils unlock targeted single-neuron therapies for neurodegenerative disorders

Researchers have developed a magnetic coil array called MagPatch that can stimulate individual neurons with precision. The device uses soft magnetic materials to boost the magnetic field, reducing the need for high current levels.

SourceAmerican Institute of Physics·JournalJournal of Vacuum Science & Technology B Microelectronics and Nanometer Structures Processing Measurement and Phenomena·DateApr 23, 2024